U.S. health officials announced Tuesday that the federal government will pay Moderna $176 million to speed development of a pandemic flu vaccine based on mRNA technology. Such a vaccine could be used to treat bird flu in people, as concern grows about H5N1 cases...
Innovative model highlights potential platform to develop novel therapies Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a new model that offers a potential platform for...
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the...
Moderna may be holding back its plans for mRNA vaccine production in Africa, but Germany’s BioNTech is filling in the space with an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). BioNTech announced Wednesday that CEPI had...
The European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with Pfizer and BioNTech over certain components of the mRNA vaccines authorized to fight Covid-19. “We are pleased to announce that the European Patent Office decided to...
